Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24603042 | 0.83 | TAS1R3 (0.47) | TAS1R3TAS1R1ALDH1A1CHRNB2CHRNB4 | |
| SCHEMBL23095373 | 0.78 | ADH1B (0.42) | TAS1R3TAS1R1MAPK1 | |
| SCHEMBL6914565 | 0.78 | IAPP (0.40) | PPARGPPARAALDH1A1 | |
| SCHEMBL20132733 | 0.77 | TAS1R3 (0.42) | TAS1R3TAS1R1ALDH1A1CHRNB2CHRNB4 | |
| SCHEMBL6450206 | 0.72 | TAS1R3 (0.57) | TAS1R3TAS1R1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL25947506 | 0.71 | ALDH1A1 (0.50) | TAS1R3TAS1R1ALDH1A1CHRNB2CHRNB4 | |
| SCHEMBL8031100 | 0.71 | ALDH1A1 (0.50) | TAS1R3TAS1R1ALDH1A1CHRNB2CHRNB4 | |
| SCHEMBL18471337 | 0.70 | TAS1R3 (0.38) | TAS1R3TAS1R1ALDH1A1CHRNB2CHRNB4 | |
| SCHEMBL18431573 | 0.70 | CA1 (0.39) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL23722464 | 0.70 | CHRNB2 (0.42) | TAS1R3TAS1R1ALDH1A1CHRNB2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208388-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200172495-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208388-B2 | Certain chemical entities, compositions, and methods | BRAF, PIK3CA, PLK1 | TAS1R3 4420/4885TAS1R1 4588/4885PPARG 1613/4885 |
| US-20200172495-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | TAS1R3 4420/4885TAS1R1 4588/4885PPARG 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.